Mycopathologia

, Volume 176, Issue 3–4, pp 211–217 | Cite as

Differential Sensitivity of the Species of Candida parapsilosis Sensu Lato Complex Against Statins

  • Judit Szenzenstein
  • Attila Gácser
  • Zsuzsanna Grózer
  • Zoltán Farkas
  • Katalin Nagy
  • Csaba Vágvölgyi
  • János Márki-Zay
  • Ilona Pfeiffer
Article

Abstract

Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis are human fungal pathogens with clinical importance. The recently reclassified three closely related species have significant variation in virulence, clinical prevalence and susceptibility characteristics to different antifungal compounds. The aim of this study was to investigate the in vitro activity of atorvastatin and fluvastatin against C. metapsilosis, C. orthopsilosis and C. parapsilosis. Susceptibility tests showed that C. parapsilosis was the most sensitive while C. orthopsilosis was the least susceptible species to both drugs. On the basis of the differential sensitivity, we developed a simple, reliable and highly cost-effective plate assay to distinguish these closely related species. Applying this method, 54 isolates belonging to the C. parapsilosis sensu lato complex deposited in Szeged Microbial Collection could be sorted into the three species with 100 % probability.

Keywords

Atorvastatin Fluvastatin Candida metapsilosis C. orthopsilosis C. parapsilosis 

References

  1. 1.
    Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol. 2005;43(1):284–92. doi:10.1128/JCM.43.1.284-292.2005.PubMedCrossRefGoogle Scholar
  2. 2.
    Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21(4):606–25. doi:10.1128/CMR.00013-08.PubMedCrossRefGoogle Scholar
  3. 3.
    van Asbeck EC, Clemons KV, Stevens DA. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol. 2009;35(4):283–309. doi:10.3109/10408410903213393.PubMedCrossRefGoogle Scholar
  4. 4.
    de Toro M, Torres MJ, Maite R, Aznar J. Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect. 2010. doi:10.1111/j.1469-0691.2010.03302.x.Google Scholar
  5. 5.
    Thierry G, Morio F, Le Pape P, Gay-Andrieu F, Barre O, Miegeville M. Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®. Pathol Biol (Paris). 2011;59(1):52–6. doi:10.1016/j.patbio.2010.07.019.
  6. 6.
    Endo A. A gift from nature: the birth of the statins. Nat Med. 2008;14(10):1050–2. doi:10.1038/nm1008-1050.PubMedCrossRefGoogle Scholar
  7. 7.
    Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–87.PubMedCrossRefGoogle Scholar
  8. 8.
    Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett. 2006;262(1):9–13. doi:10.1111/j.1574-6968.2006.00370.x.PubMedCrossRefGoogle Scholar
  9. 9.
    Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol. 2002;51(2):105–9.PubMedGoogle Scholar
  10. 10.
    Song JL, Lyons CN, Holleman S, Oliver BG, White TC. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med Mycol. 2003;41(5):417–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Kocsube S, Toth M, Vagvolgyi C, Doczi I, Pesti M, Pocsi I, et al. Occurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol. 2007;56(Pt 2):190–5. doi:10.1099/jmm.0.46838-0.PubMedCrossRefGoogle Scholar
  12. 12.
    Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118. doi:10.1146/annurev.pharmtox.45.120403.095748.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Judit Szenzenstein
    • 1
  • Attila Gácser
    • 1
  • Zsuzsanna Grózer
    • 1
  • Zoltán Farkas
    • 1
  • Katalin Nagy
    • 2
  • Csaba Vágvölgyi
    • 1
  • János Márki-Zay
    • 3
  • Ilona Pfeiffer
    • 1
  1. 1.Department of Microbiology, Faculty of Science and InformaticsUniversity of SzegedSzegedHungary
  2. 2.Faculty of DentistryUniversity of SzegedSzegedHungary
  3. 3.Solvo BiotechnologySzegedHungary

Personalised recommendations